Winston Pharmaceutcl (WPHM) 0.0180 $WPHM
Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.23 (-0.04), PFE: 33.76 (-0.21), AMGN: 144.55 (-1.90), ZYNE: 7.17 (-0.48), NKTR: 13.61 (-0.77), AZN: 27.87 (+0.01), VBAY: (), PTIE: 1.98 (-0.05)
Crohn's Disease - Pipeline Review, H1 2015
M2 - Fri Sep 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lccxr6/crohns_disease) has announced the addition of the "Crohn's Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Partial list of the 70 companies mentioned in this comprehensive report: - 4SC - AB Science - Baliopharm - BIOCAD - Calypso Biotech - Celgene - Daiichi Sankyo - DBV Technologies - Effimune - Eisai - Farmacija d.o.o. Tuzla - Ferring International Center - Galapagos - Genentech - iCo Therapeutics - Idera Pharmaceuticals - Johnson & Johnson - Kyorin Pharmaceutical - Mabion - Mesoblast - Neovacs - Oncobiologics - Oncodesign - Pfenex - Pfizer - Qu Biologics - Receptos - Sandoz International - Selexys Pharmaceuticals - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Virobay - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lc...ns_disease
JNJ: 116.14 (+0.51), IDRA: 1.39 (-0.09), TEVA: 48.44 (-1.57), CELGZ: 1.54 (+0.12)
Cancer Pain Therapeutics Pipeline Review, H1 2015 - 28 Companies & 34 Drug Profiles
M2 - Fri Jul 31, 8:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sbhbp/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Grunenthal GmbH - GW Pharmaceuticals Plc - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Nippon Kayaku Co., Ltd. - Northern Light Pharmaceuticals AB - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - Recordati S.p.A. - Sorrento Therapeutics, Inc. - Virobay Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - AMS-410 ER12 - ANG-2002 - BBI-11008 - calpastatin - cebranopadol - crotalphine - DD-04107 - dexmedetomidine hydrochloride - dronabinol - Drug for Cancer Neuropathic Pain - fentanyl - fentanyl citrate - fulranumab - HS-198 - hydromorphone hydrochloride - INT-0028 - IPP-102199 - ketamine hydrochloride ER - KLS-2010 - methadone hydrochloride - nabiximols - Nervarna - NKTR-192 - Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - PGN-202 - PL-265 - Q-201 - QX-314 - resiniferatoxin - saracatinib difumarate - Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule to Antagonize Chemokine Receptor for Cancer Pain For more information visit http://www.researchandmarkets.com/research/5s...ancer_pain
BDSI: 2.23 (-0.04), PFE: 33.76 (-0.21), AMGN: 144.55 (-1.90), SRNE: 5.46 (-0.16), ZYNE: 7.17 (-0.48), NKTR: 13.61 (-0.77), AZN: 27.87 (+0.01), VBAY: (), PTIE: 1.98 (-0.05)
Postherpetic Neuralgia - Pipeline Review, H1 2015
M2 - Thu Jun 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg24hw/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Aestus Therapeutics - Allergan - Arcion Therapeutics - Astellas Pharma - Daewoong Pharmaceutical - Daiichi Sankyo - Immune Pharmaceuticals - Intellipharmaceutics International - Merck & Co. - NeurAxon - Nuvo Research - Pfizer - Phosphagenics - Purdue Pharma - Relmada Therapeutics - Scilex Pharmaceuticals - Spinifex Pharmaceuticals - Teva Pharmaceutical Industries - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/hg...stherpetic
AGN: 217.74 (-7.98), IPCI: 1.50 (-0.06), MRK: 55.43 (-0.45), TEVA: 48.44 (-1.57), IMNP: 0.36 (-0.02)
Global Osteoarthritis Market 2015-2019 - Increased Competition in the Market
M2 - Fri Apr 10, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7rntn4/global) has announced the addition of the "Global Osteoarthritis Market 2015-2019" report to their offering. The Global OA market to grow at a CAGR of 8.55 percent over the period 2014-2019. OA is a condition in which the cartilage, a material that cushions the joints, breaks down. This leads to stiffness, inflammation, pain, and loss of joint movement. The exact etiology of OA is not fully understood. Obesity, overuse of the joint, weak thigh muscles, aging, and genetics are some of the common risk factors of OA; OA symptoms usually develop progressively. At first, there may be stiffness that appears to be more a niggle than a medical concern. Treatment is given depending on the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise. This report covers the present scenario and the growth prospects of the Global OA market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the symptomatic treatment and therapeutics of OA that are available in the market. The market can be divided into three segments: Anti-inflammatories, Pain Relievers, and Drugs to Restore Articular Cartilage. The presence of several large and small pharmaceutical companies has resulted in intense competition. Many different classes of drugs, such as NSAIDs, simple analgesics, corticosteroids, and opioids that provide effective relief from discomfort in the early-to-mid stages of osteoarthritis are present in the market. According to the report, certain cellular processes that take place during aging in the human body might contribute to the development of osteoarthritis in some people. As a person ages, the water content of the cartilage increases and the protein makeup of the cartilage degenerates. Thus, an increase in the elderly population drives the market growth. Further, the report states that many patients do not undergo treatment as they are unaware of the disease and its symptoms. In addition, many others avoid drug therapies owing to their side effects, take medications irregularly, or stop consuming them altogether. Key Vendors - Abbott Laboratories - Johnson & Johnson - Novartis - Pfizer Other Prominent Vendors - Abiogen Pharma - Ampio pharmaceuticals - BioDelivery Sciences International - CrystalGenomics - Daiichi Sankyo - Eli Lilly - Horizon Pharma - Iroko Pharmaceuticals - Merck - Nuvo Research - Regeneus - Sanofi - SantoSolve - Smith & Nephew - Winston Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Osteoarthritis Pipeline Assessment - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7rntn4/global
BDSI: 2.23 (-0.04), SNN: 31.30 (-1.32), JNJ: 116.14 (+0.51), ABT: 36.88 (-1.03), MRK: 55.43 (-0.45), HZNP: 15.01 (-1.24), LLY: 74.26 (-0.07), NVS: 77.33 (+0.23)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 2.23 (-0.04), ACRX: 2.50 (-0.07), EGLT: 4.42 (-0.33), AMGN: 144.55 (-1.90), NKTR: 13.61 (-0.77)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 2.23 (-0.04), PFE: 33.76 (-0.21), AMGN: 144.55 (-1.90), AXN: 0.62 (unch), SRNE: 5.46 (-0.16), NKTR: 13.61 (-0.77), EGLT: 4.42 (-0.33), AZN: 27.87 (+0.01), VBAY: ()
Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.23 (-0.04), PFE: 33.76 (-0.21), AMGN: 144.55 (-1.90), ZYNE: 7.17 (-0.48), NKTR: 13.61 (-0.77), AZN: 27.87 (+0.01), VBAY: (), PTIE: 1.98 (-0.05)
Crohn's Disease - Pipeline Review, H1 2015
M2 - Fri Sep 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lccxr6/crohns_disease) has announced the addition of the "Crohn's Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Partial list of the 70 companies mentioned in this comprehensive report: - 4SC - AB Science - Baliopharm - BIOCAD - Calypso Biotech - Celgene - Daiichi Sankyo - DBV Technologies - Effimune - Eisai - Farmacija d.o.o. Tuzla - Ferring International Center - Galapagos - Genentech - iCo Therapeutics - Idera Pharmaceuticals - Johnson & Johnson - Kyorin Pharmaceutical - Mabion - Mesoblast - Neovacs - Oncobiologics - Oncodesign - Pfenex - Pfizer - Qu Biologics - Receptos - Sandoz International - Selexys Pharmaceuticals - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Virobay - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lc...ns_disease
JNJ: 116.14 (+0.51), IDRA: 1.39 (-0.09), TEVA: 48.44 (-1.57), CELGZ: 1.54 (+0.12)
Cancer Pain Therapeutics Pipeline Review, H1 2015 - 28 Companies & 34 Drug Profiles
M2 - Fri Jul 31, 8:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sbhbp/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Grunenthal GmbH - GW Pharmaceuticals Plc - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Nippon Kayaku Co., Ltd. - Northern Light Pharmaceuticals AB - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - Recordati S.p.A. - Sorrento Therapeutics, Inc. - Virobay Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - AMS-410 ER12 - ANG-2002 - BBI-11008 - calpastatin - cebranopadol - crotalphine - DD-04107 - dexmedetomidine hydrochloride - dronabinol - Drug for Cancer Neuropathic Pain - fentanyl - fentanyl citrate - fulranumab - HS-198 - hydromorphone hydrochloride - INT-0028 - IPP-102199 - ketamine hydrochloride ER - KLS-2010 - methadone hydrochloride - nabiximols - Nervarna - NKTR-192 - Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - PGN-202 - PL-265 - Q-201 - QX-314 - resiniferatoxin - saracatinib difumarate - Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule to Antagonize Chemokine Receptor for Cancer Pain For more information visit http://www.researchandmarkets.com/research/5s...ancer_pain
BDSI: 2.23 (-0.04), PFE: 33.76 (-0.21), AMGN: 144.55 (-1.90), SRNE: 5.46 (-0.16), ZYNE: 7.17 (-0.48), NKTR: 13.61 (-0.77), AZN: 27.87 (+0.01), VBAY: (), PTIE: 1.98 (-0.05)
Postherpetic Neuralgia - Pipeline Review, H1 2015
M2 - Thu Jun 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg24hw/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Aestus Therapeutics - Allergan - Arcion Therapeutics - Astellas Pharma - Daewoong Pharmaceutical - Daiichi Sankyo - Immune Pharmaceuticals - Intellipharmaceutics International - Merck & Co. - NeurAxon - Nuvo Research - Pfizer - Phosphagenics - Purdue Pharma - Relmada Therapeutics - Scilex Pharmaceuticals - Spinifex Pharmaceuticals - Teva Pharmaceutical Industries - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/hg...stherpetic
AGN: 217.74 (-7.98), IPCI: 1.50 (-0.06), MRK: 55.43 (-0.45), TEVA: 48.44 (-1.57), IMNP: 0.36 (-0.02)
Global Osteoarthritis Market 2015-2019 - Increased Competition in the Market
M2 - Fri Apr 10, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7rntn4/global) has announced the addition of the "Global Osteoarthritis Market 2015-2019" report to their offering. The Global OA market to grow at a CAGR of 8.55 percent over the period 2014-2019. OA is a condition in which the cartilage, a material that cushions the joints, breaks down. This leads to stiffness, inflammation, pain, and loss of joint movement. The exact etiology of OA is not fully understood. Obesity, overuse of the joint, weak thigh muscles, aging, and genetics are some of the common risk factors of OA; OA symptoms usually develop progressively. At first, there may be stiffness that appears to be more a niggle than a medical concern. Treatment is given depending on the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise. This report covers the present scenario and the growth prospects of the Global OA market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the symptomatic treatment and therapeutics of OA that are available in the market. The market can be divided into three segments: Anti-inflammatories, Pain Relievers, and Drugs to Restore Articular Cartilage. The presence of several large and small pharmaceutical companies has resulted in intense competition. Many different classes of drugs, such as NSAIDs, simple analgesics, corticosteroids, and opioids that provide effective relief from discomfort in the early-to-mid stages of osteoarthritis are present in the market. According to the report, certain cellular processes that take place during aging in the human body might contribute to the development of osteoarthritis in some people. As a person ages, the water content of the cartilage increases and the protein makeup of the cartilage degenerates. Thus, an increase in the elderly population drives the market growth. Further, the report states that many patients do not undergo treatment as they are unaware of the disease and its symptoms. In addition, many others avoid drug therapies owing to their side effects, take medications irregularly, or stop consuming them altogether. Key Vendors - Abbott Laboratories - Johnson & Johnson - Novartis - Pfizer Other Prominent Vendors - Abiogen Pharma - Ampio pharmaceuticals - BioDelivery Sciences International - CrystalGenomics - Daiichi Sankyo - Eli Lilly - Horizon Pharma - Iroko Pharmaceuticals - Merck - Nuvo Research - Regeneus - Sanofi - SantoSolve - Smith & Nephew - Winston Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Osteoarthritis Pipeline Assessment - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7rntn4/global
BDSI: 2.23 (-0.04), SNN: 31.30 (-1.32), JNJ: 116.14 (+0.51), ABT: 36.88 (-1.03), MRK: 55.43 (-0.45), HZNP: 15.01 (-1.24), LLY: 74.26 (-0.07), NVS: 77.33 (+0.23)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 2.23 (-0.04), ACRX: 2.50 (-0.07), EGLT: 4.42 (-0.33), AMGN: 144.55 (-1.90), NKTR: 13.61 (-0.77)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 2.23 (-0.04), PFE: 33.76 (-0.21), AMGN: 144.55 (-1.90), AXN: 0.62 (unch), SRNE: 5.46 (-0.16), NKTR: 13.61 (-0.77), EGLT: 4.42 (-0.33), AZN: 27.87 (+0.01), VBAY: ()
